Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026

Same author

ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.

Science advances·2026

Same author

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

Oncogene·2026

Same author

ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity.

bioRxiv : the preprint server for biology·2026

Same author

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.

bioRxiv : the preprint server for biology·2026

Same author

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Signal transduction and targeted therapy·2025

Same journal

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer·2026

Same journal

GPNMB-directed CAR-T cell therapies for solid tumors.

Nature cancer·2026

Same journal

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026

Same journal

Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.

Nature cancer·2026

Same journal

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026

Same journal

GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells.

Nature cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Targeting therapy-persistent residual disease.

Xiaoxiao Sun¹, Lani F Wu², Steven J Altschuler³

¹Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.

|September 17, 2024

Summary

This summary is machine-generated.

Targeting therapy-persistent cancer cells in residual disease can improve anti-cancer treatment effectiveness and durability. Overcoming barriers to clinical implementation is crucial for developing new strategies against acquired drug resistance and disease relapse.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

Oncology
Cancer Therapy
Pharmacology

Background:

Acquired drug resistance leads to disease relapse, limiting systemic anti-cancer agent efficacy.
Persistent cancer cells in residual disease are a key challenge in current cancer therapies.
Targeting these persistent cells offers a strategy to improve treatment durability.

Purpose of the Study:

To discuss the complexities of targeting therapy-persistent residual disease.
To outline key steps for developing clinical strategies against residual cancer.
To address barriers in implementing persister-directed approaches in oncology.

Main Methods:

Review of preclinical findings on therapy-persistent cells.
Analysis of clinical complexities in targeting residual disease.
Discussion of challenges in developing persister-directed therapies.

Main Results:

Significant barriers exist in translating persister-directed approaches to clinical practice.
Preclinical strategies show promise but require further development for clinical application.
Understanding and overcoming resistance mechanisms is vital.

Conclusions:

Developing clinical strategies to target therapy-persistent residual disease is essential.
Addressing current complexities is key to enhancing cancer treatment efficacy and durability.
Further research and clinical development are needed to overcome implementation barriers.